170 related articles for article (PubMed ID: 6541487)
1. Effect of enzyme induction on the disposition of lorcainide in rats following intravenous and oral administration.
Plänitz V; Jähnchen E
Arzneimittelforschung; 1984; 34(6):669-71. PubMed ID: 6541487
[TBL] [Abstract][Full Text] [Related]
2. Prehepatic and hepatic first-pass metabolism of lorcainide in rats.
Plänitz V; Grönniger J; Jähnchen E
Arzneimittelforschung; 1985; 35(6):923-6. PubMed ID: 4026917
[TBL] [Abstract][Full Text] [Related]
3. Lorcainide disposition kinetics in arrhythmia patients.
Kates RE; Keefe DL; Winkle RA
Clin Pharmacol Ther; 1983 Jan; 33(1):28-34. PubMed ID: 6848296
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
Echt DS; Mitchell LB; Kates RE; Winkle RA
Circulation; 1983 Aug; 68(2):392-9. PubMed ID: 6861314
[TBL] [Abstract][Full Text] [Related]
5. Lorcainide kinetics and protein binding in patients with end-stage renal disease.
Somani P; Simon V; Gupta RK; King P; Shapiro RS; Stockard H
Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):121-5. PubMed ID: 6715079
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics and tissue distribution of the new antiarrhythmic agent lorcainide (R 15889) in rats.
Klotz U; Golbs E
Arzneimittelforschung; 1980; 30(4):619-21. PubMed ID: 7190402
[TBL] [Abstract][Full Text] [Related]
7. Disposition and antiarrhythmic effect of lorcainide.
Klotz U; Müller-Seydlitz P; Heimburg P
Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):152-8. PubMed ID: 376458
[TBL] [Abstract][Full Text] [Related]
8. Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide.
Pottage A
Am J Cardiol; 1983 Sep; 52(6):24C-31C. PubMed ID: 6414279
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent.
Klotz U; Müller-Seydlitz P; Heimburg P
Clin Pharmacokinet; 1978; 3(5):407-18. PubMed ID: 699462
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide.
Winkle RA; Keefe DL; Rodriguez I; Kates RE
Am J Cardiol; 1984 Feb; 53(4):544-51. PubMed ID: 6198895
[TBL] [Abstract][Full Text] [Related]
11. Lorcainide in the prophylaxis of ventricular arrhythmias in acute myocardial infarction.
Leinonen H; Heikkilä J; Sundberg S; Gordin A
Ann Clin Res; 1984; 16(1):18-22. PubMed ID: 6378045
[TBL] [Abstract][Full Text] [Related]
12. Lorcainide. I. Saturable presystemic elimination.
Jähnchen E; Bechtold H; Kasper W; Kersting F; Just H; Heykants J; Meinertz T
Clin Pharmacol Ther; 1979 Aug; 26(2):187-95. PubMed ID: 455887
[No Abstract] [Full Text] [Related]
13. The use and limitations of deuterated lorcainide in metabolism and pharmacokinetic studies.
Gelijkens CF; Van Peer A; Lenoir H; Knaeps A; Woestenborghs R; Heykants J
Biomed Mass Spectrom; 1985 Jan; 12(1):38-42. PubMed ID: 3157409
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic investigations of Craviten. IV. First-pass metabolism in rats.
Danek A; Witek J
Pol J Pharmacol Pharm; 1980; 32(6):949-53. PubMed ID: 7243692
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of 3H-pipethiaden after single oral and intravenous administration in rats.
Lapka R; Franc Z; Smolik S
Arzneimittelforschung; 1985; 35(2):486-8. PubMed ID: 4039570
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of lorcainide.
Keefe DL
Am J Cardiol; 1984 Aug; 54(4):18B-21B. PubMed ID: 6465043
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with lorcainide (R 15 889), a new anti-arrhythmic drug.
Kesteloot H; Stroobandt R
Arch Int Pharmacodyn Ther; 1977 Dec; 230(2):225-34. PubMed ID: 603318
[TBL] [Abstract][Full Text] [Related]
18. Single dose pharmacokinetics and bioavailability of glucosamine in the rat.
Aghazadeh-Habashi A; Sattari S; Pasutto F; Jamali F
J Pharm Pharm Sci; 2002; 5(2):181-4. PubMed ID: 12207871
[TBL] [Abstract][Full Text] [Related]
19. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability and saturation of the presystemic metabolism of oral lorcainide therapy initiated in three different dose regimens.
Amery WK; Heykants J; Bruyneel K; Terryn R
Eur J Clin Pharmacol; 1983; 24(4):517-9. PubMed ID: 6861866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
